Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsResearchersKey papersJournalsOpen accessInstitutions
ScholarIQanswers from OpenAlex

Bladder and Urothelial Cancer Treatments

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the diagnosis, treatment, and management of bladder cancer, particularly urothelial carcinoma. It covers topics such as chemotherapy, cystectomy, neoadjuvant therapy, molecular characterization, metastatic bladder cancer, guidelines for management, and immunotherapy. The papers provide insights into various aspects of bladder cancer research and clinical practice.

309
Works

How has Bladder and Urothelial Cancer Treatments's publication output changed over time?

ScholarIQpublication output · 2004–2023

Output grew0% over the shown period — from 1 works in 2004 to 1 in 2023.

1
1
1
1
2
1
1
4
2
1
2004201020142015201620172018202020212023

What are the most-cited papers on Bladder and Urothelial Cancer Treatments?

ScholarIQmost cited works
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer
The Lancet. 20163,735 Citations
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin
New England Journal of Medicine. 20173,424 CitationsOPEN ACCESS
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, Éva Compérat, Nigel C. Cowan, Georgios Gakis, Virginia Hernández, Estefania Linares Espinós, Anja Lorch, Y. Neuzillet, Mathieu Rouanne, George N. Thalmann, Erik Veskimäe, María J. Ribal, Antoine G. van der Heijden
European Urology. 20202,166 Citations
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
J. Alfred Witjes, Thierry Lebrét, Éva Compérat, Nigel C. Cowan, Maria De Santis, H.M. Bruins, Virginia Hernández, Estefanía Linares, James Dunn, Mathieu Rouanne, Y. Neuzillet, Erik Veskimäe, Antoine G. van der Heijden, Georgios Gakis, María J. Ribal
European Urology. 20161,516 Citations
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles, Se Hoon Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Daniel P. Petrylak, Robert J Laliberte, Jing Wang, Bo Huang, Craig B. Davis, Camilla Fowst, Nuno Costa, John A. Blake-Haskins, Alessandra di Pietro, Petros Grivas
New England Journal of Medicine. 20201,501 CitationsOPEN ACCESS

Where is Bladder and Urothelial Cancer Treatments research published, and who funds it?

ScholarIQvenues & funding sources

TOP FUNDERS

National Science Foundation
NIH
Wellcome Trust
European Research Council
Funder breakdown is a member featureSign up free to unlock

How much of the research on Bladder and Urothelial Cancer Treatments is open access?

ScholarIQopen access share
60%OPEN ACCESS
Gold
0%
Green
20%
Hybrid
7%
Bronze
33%
Closed
40%

Related on ScholarIQ

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Paper
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Paper
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
Paper
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
Paper
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
Paper
Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer
Paper
470M+ articles · free account